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MaSuccessful implementation of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines
hinges on a clear understanding of the clinician-patient risk discussion (CPRD). This is a dialogue between the clinician and
patient about potential for atherosclerotic cardiovascular disease risk reduction beneﬁts, adverse effects, drug-drug inter-
actions, and patient preferences. Designed especially for primary prevention patients, this process of shared decisionmaking
establishes the appropriateness of a statin for a speciﬁc patient. CPRD respects the autonomy of an individual striving to
make an informed choice alignedwith personal values and preferences. Dedicating sufﬁcient time tohigh-quality CPRDoffers
an opportunity to strengthen clinician-patient relationships, patient engagement, and medication adherence. We review
the guideline-recommended CPRD, the general concept of shared decision making and decision aids, the American College
of Cardiology/American Heart Association Risk Estimator application as an implementation tool, and address potential
barriers to implementation. (J Am Coll Cardiol 2015;65:1361–8) © 2015 by the American College of Cardiology Foundation.Tell me, I may listen.
Teach me, I may remember.
Involve me, I will do it.
—Chinese proverb
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ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College
of Cardiology
AHA = American Heart
Association
app = application
ASCVD = atherosclerotic
cardiovascular disease
CPRD = clinician-patient
risk discussion
LDL-C = low-density
lipoprotein cholesterol
NNH = number needed-
to-harm
NNT = number needed-to-treat
SDM = shared decision making
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1362ACC/AHA Risk Estimator application (app) as
an implementation tool (Figure 1), and
address potential barriers to implementa-
tion. We aim to synthesize evidence with
our clinical experience to maximize clinical
relevance.
WHAT THE GUIDELINES SAY
In primary prevention, the 2013 ACC/AHA
cholesterol guidelines recommend esti-
mating the 10-year ASCVD risk with pooled
cohort equations every 4 to 6 years in adults
40 to 75 years of age without clinical ASCVD
or diabetes who have a low-density lipo-
protein cholesterol (LDL-C) level of 70 to
189 mg/dl. However, the pooled cohortequations should not be used to re-estimate risk in
statin-treated patients or after a short course of life-
style change. The guidelines advise that a statin may
be indicated when a patient has either 1) an estimated
10-year ASCVD (heart attack/stroke) risk of $7.5%
(Class I, Level of Evidence: A) or 2) estimated risk of
5% to 7.4% (Class IIa, Level of Evidence: B).
The guideline panel compared the estimated
number needed-to-treat (NNT) to avoid an ASCVD
event with the estimated number needed-to-harm
(NNH) (with respect to diabetes; not considered
equivalent to an ASCVD event) to identify evidence-
based 10-year ASCVD risk thresholds for initiation of
moderate-intensity or high-intensity statin therapy.
For a moderate-intensity statin, the estimated NNT
vs. NNH was 36 to 44 vs. 100 for the $7.5% risk
threshold and 57 to 67 vs 100 for patients with 5% to
7.4% risk. For a high-intensity statin, respective
estimates were 30 vs. 33 for $7.5% risk and 44 vs. 33
for 5% to 7.4% risk. Therefore, these estimates sup-
ported net clinical beneﬁt with moderate-intensity
statin therapy in each risk group and also for high-
intensity statin therapy in those with $7.5% risk.
Starting a statin, which is commonly a lifelong
therapy, is not a trivial decision and the guidelines
recommend holding a CPRD (1,6). Elements of a
comprehensive CPRD are shown in Table 1. Impor-
tantly, the appropriateness of statin therapy can only
be established through this process of SDM (7–9). Per
the guidelines, the estimation of 10-year risk per se
should not be used in isolation to prescribe a statin.
The 2013 ACC/AHA guidelines are reﬂective of the
idea that: “Guidelines must not replace clinicians’
compassionate and mindful engagement of the
patient in making decisions together. This is the
optimal practice of evidence-based medicine” (10).
Accordingly, the 10-year ASCVD risk estimate servesas a starting point for a patient-clinician dialogue.
While discussion about the expected beneﬁts and
risks of medication should generally occur with all
prescriptions, such discussions too often occur
haphazardly or not at all (7–9). By bringing the CPRD
to the forefront, the 2013 ACC/AHA cholesterol
guidelines reinforce the need for a more consistent
and reliable dialogue in connection with writing a
prescription. Emphasis on the CPRD acknowledges
that each case is unique and that patient preferences
matter, providing a ﬂexible framework that values
the art of medicine.
IMPORTANCE OF SDM
The clinical role of SDM was recently reviewed (9,11).
By deﬁnition, the decision is shared, but not neces-
sarily equally. Depending on the situation, either the
patient or clinician may take the lead in the process
(11). Attention to SDM has increased in the United
States, in particular because of changes in health
policy, the availability of greater numbers of decision
aids, and new funding opportunities through the
Patient-Centered Outcomes Research Institute (9).
It is not a matter of if—but rather of when—SDM will
be more widely implemented.
This is supported by numerous studies. A survey
of patients undergoing angiograms indicated that
patients generally want to take an active role in SDM,
although they appreciate their physician taking a
lead on problem-solving tasks (12). In a survey of
1,340 patients older than 40 years of age, approxi-
mately 70% reported a preference for SDM (13). This is
consistent with a survey of 6,636 participants in
contemporary acute myocardial infarction registries,
where 68% preferred being actively involved in
decision making (14).
DECISION AIDS AND THE
ACC/AHA RISK ESTIMATOR APP
Participation in SDM requires an informed patient. In
the randomized Statin Choice Trial of 150 patients
with diabetes, a decision aid improved risk commu-
nication, beliefs, and decisional conﬂict (15). Whereas
the focus is on the patient, decision aids can be used
by both patients and clinicians, either together during
the clinical encounter, or separately between visits.
To increase relevant health knowledge and promote
patient-clinician dialogue, decision aids may be pro-
duced digitally or on paper.
The ACC/AHA Risk Estimator app was developed to
help clinicians and patients implement SDM related
to the 2013 ACC/AHA cholesterol guidelines. The app
is widely available and easily accessed via computers,
FIGURE 1 Smartphone Screenshot of the 2013 ACC/AHA Guidelines
ASCVD Risk Estimator App
Additional screenshots are provided in the Online Appendix 1. The app can
also be downloaded from iTunes (16) or Google Play (17), or the web version
can be launched from a computer (18). ACC ¼ American College of Cardiology;
AHA ¼ American Heart Association; ASCVD ¼ atherosclerotic cardiovascular
disease.
J A C C V O L . 6 5 , N O . 1 3 , 2 0 1 5 Martin et al.
A P R I L 7 , 2 0 1 5 : 1 3 6 1 – 8 Clinician-Patient Risk Discussion
1363tablets, or smartphones (Figure 1, Online Appendix 1)
(16–18). Easy availability compared with previous risk
scores was a critical step in facilitating use by patients
and care providers alike. It was also designed with the
hope that it could be integrated into the electronic
medical record for automatic calculation and display.
The app not only facilitates estimation of 10-year
ASCVD risk for those 40 to 79 years old, but also
allows for lifetime risk estimation for those 20 to
59 years old. This latter risk is based on the grouping of
risk factor levels into 5 strata, related towhether all risk
factors are optimal,$1 risk factor is not optimal,$1 risk
factor is elevated, 1 major risk factor is present, or $2
major risk factors are present (19). Using the app will
facilitate linkage to lifestyle (20) and obesity/over-
weight (21) guideline recommendations, as these are
highlighted in the app. For example, the app’s patient-
oriented weight management section advises that
“losing just 3-5% of body weight can improve blood
pressure and cholesterol levels and reduce the risk for
cardiovascular disease and diabetes.”
COMMUNICATING ASCVD RISK AND POTENTIAL FOR
STATIN BENEFIT. A key aspect of CPRD is commu-
nicating that an individual’s risk estimate is a group
average from a representative sample. One straight-
forward and reasonable way to communicate an
estimated 10-year ASCVD risk of 19% is to say, “of
100 patients like you, 19 would be expected to have a
stroke or heart attack in the next 10 years.” Whereas
for some patients this description of risk may be
sufﬁcient, others may require additional cues. An
option is a visual aid showing absolute risk and
incremental beneﬁts/risks associated with drug
therapy. This is currently available in a web-based
tool (22) and is being considered for inclusion in
future versions of the ACC/AHA Risk Estimator app.
A recent systematic review on risk communication
did not establish the superiority of any single method
for conveying risk, but it suggests that using visual
aids (e.g., icon arrays, risk pictographs) can improve
patient understanding and satisfaction (23). Whereas
some tools have focused exclusively on longevity (24),
nonfatal ASCVD outcomes are costly and nontrivial to
the patients and their families (25,26). The NNT data
appeals to clinicians, but it appears to decrease patient
understanding (23). Previous studies have generally
been small and heterogeneous in methodology, thus
further high-quality, patient-oriented research
comparing different presentation styles is needed to
better understand how to best enhance patient-
clinician interactions (9,23,27,28). In the meantime, a
group of experts has provided a comprehensive set of
“best practices” in presenting quantitative risk infor-
mation through decision aids (29).
TABLE 1 Checklist for Clinician-Patient Risk Discussion
Review risk factors and the 10-year risk estimate.
Address treatable nonlipid risk factors.
Review diet and physical activity habits.
Endorse a healthy lifestyle and provide relevant advice/materials/referrals.
Discuss potential risk reduction from lipid-lowering therapy and recommend
statins as ﬁrst-line therapy.
Discuss the potential for adverse effects/drug-drug interactions.
Assess conﬁdence in risk-based treatment decisions; if uncertain, offer further
options to reﬁne risk estimate.
Invite the patient to ask questions and express values/preferences.
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compare an individual’s risk estimate with someone
of the same age, sex, and race who has optimal risk
factors, deﬁned as a total cholesterol of 170 mg/dl,
high-density lipoprotein cholesterol of 50 mg/dl,
untreated systolic blood pressure of 110 mm Hg,
no diabetes history, and absence of current smoking.
Personalizing the presentation may lead to more
effective SDM.
Once patients understand their ASCVD risk, the
next step is a discussion about risk reducing in-
terventions, including lifestyle changes and initiation
of a statin. Patients at higher risk generally understand
that they are more likely to beneﬁt from more inten-
sive therapy. For those in a statin beneﬁt group, high-
intensity statin regimens ($50% anticipated LDL-C
lowering) are recommended to those at highest risk.
As noted previously (4), meta-analyses have shown a
w20% relative risk reduction per 39 mg/dl lowering of
LDL-C. Moderate-intensity regimens (30% to <50%
LDL-C lowering) are reserved for those at lower risk
who still may beneﬁt from statin therapy. The ACC/
AHA Risk Estimator app helps providers make appro-
priate treatment choices by listing the various statins
and respective doses for the different intensities. In
general, patients and clinicians should aim for the
maximum tolerated regimen, however for those pre-
disposed to adverse effects or for whom drug-drug
interactions require a lower dose and favor speciﬁc
statins, a moderate-intensity statin is preferred.
WHEN THE RISK-BASED TREATMENT DECISION IS
UNCERTAIN. As indicated in the ACC/AHA Risk Esti-
mator app, if the risk-based treatment decision is
uncertain after 10-year risk is estimated, which may
be common in cases where risk is not greatly
elevated, then the patient and clinician should take
into consideration additional factors that modify the
risk estimate. These include a family history ofpremature ASCVD, elevated lifetime risk, LDL-C $160
mg/dl, an elevated coronary artery calcium score
or $75th percentile based on age, sex, and ethnicity, a
high-sensitivity C-reactive protein level $2.0 mg/l, or
an ankle-brachial index <0.9. Importantly, lifetime
risk is primarily intended to enhance discussion and
promotion of an optimal lifestyle; it is not intended
per se to dictate statin prescriptions (19).
DISCUSSING RISK OF STATIN ADVERSE EFFECTS. In
the discussion of potential adverse effects, an ideal
CPRD weighs expected beneﬁts and risks, conveying
the concept of net beneﬁt. When addressing statin
adverse effects with a patient, one may consider the
5 Ms: metabolism, muscle, medication interactions,
major organ effects, and memory (30). The 2013
ACC/AHA cholesterol guideline emphasizes the safety
of statins when used in patients similar to those
enrolled in clinical trials. The guideline indicates that
adverse effects may only begin to outweigh beneﬁts
in lower-risk groups and that different margins of
safety may occur in patients excluded from clinical
trials (e.g., elderly, serious comorbidities).
We see value in being attuned to concerns popu-
larized in the mainstreammedia, as patients will often
be aware of these reports and factor them into de-
cisions. To this end, statin-related diabetes risk
is a topic worth prioritizing. When diabetes risk fac-
tors are present (metabolic syndrome, hemoglobin
A1c$6%, fasting glucose$100 mg/dl, body mass index
$30 kg/m2), statins are associated with a higher like-
lihood of developing diabetes or acceleration in its
diagnosis by w5 weeks due to a small hyperglycemic
effect (31). Similar risk factors predict a new diagnosis
of diabetes in those with pre-existing ASCVD (32).
Comparable drug-induced increases in glucose from
other medications, such as thiazides, have not
increased ASCVD risk. Regarding microvascular dis-
ease risk, statin use preceding diabetes diagnosis
was not associated with a higher risk over a median
follow-up of 2.7 years (33).
Therefore, statins generally seem to unmask an
underlying propensity to develop diabetes, but this
may not have major adverse macrovascular or micro-
vascular risk implications. It could be an opportunity
to underscore the beneﬁt of lifestyle changes at an
earlier stage in the natural history of the disorder.
Lifestyle changes, including avoidance of weight gain
and promotion of weight loss (34,35), are useful ways
to prevent diabetes. Moreover, crossing the threshold
to diabetes does not reduce the expected beneﬁts of
statins and reinforces the need for effective ASCVD
risk reduction (1). Generally, an estimated 5 to 9
ASCVD events may be prevented per case of diabetes
that might develop with statin therapy (36,37).
CENTRAL ILLUSTRATION Conceptual Framework for CPRD
CLINICIAN-PATIENT RISK DISCUSSION (CPRD)
CLINICIAN 
Present evidence-based clinical guidelines
in the context of clinical judgment
Personalize the presentation; consider 
visual aids (icon arrays/pictographs)
to improve patient understanding
PATIENT
Express personal 
preferences and 
make informed 
decisions
Present ACC/AHA Risk Estimator Application 
Endorse the tool as a helpful resource to aid understanding of ASCVD 
risk, diet and physical activity recommendations, weight management, 
blood cholesterol, statin benefit groups, and common CV terms. 
To be used during and in-between clinical encounters
Discuss Patient’s 10-Year Risk Estimate
•  Review ACC/AHA Risk Estimator application tool results
Discuss Options to Reduce ASCVD Risk
Lifestyle changes (in all)
•  Review diet and physical activity habits
•  Endorse lifestyle changes 
•  Explain benefits of a healthy lifestyle to improve blood pressure
and cholesterol levels and reduce the risk for ASCVD and diabetes
Initiation of statin (not automatic)
•  Explain benefits to improve cholesterol levels and reduce ASCVD risk
•  Note that statin therapy is commonly lifelong: Patient will likely need 
to continue therapy indefinitely to maintain cholesterol levels
Discuss Potential for Statin Adverse Effects (The 5 Ms) 
•  Metabolism: Small risk of new-onset diabetes in those predisposed 
•  Muscle: Range of muscle symptoms can occur 
•  Medication interactions: Possible prescription interactions
•  Major organ effects: Rare possibility of major organ effects
•  Memory: The guidelines found no evidence for cognitive impairment
Discuss Patient Questions/Values/Preferences
•  Review patient values and preferences
•  If patient lacks confidence to make decisions, review factors that 
modify risk if a risk decision is uncertain: family history of premature 
ASCVD; LDL-C ≥ 160 mg/dl; an elevated coronary artery calcium score 
or ≥ 75th percentile based on age, sex, and ethnicity; hs-C-reactive 
protein (CRP) level ≥ 2.0 mg/l; ankle brachial index (ABI) < 0.9
•  Patient may desire time to review information before making decisions
Benefits of CPRD
•  Strengthen clinician-patient relationships
•  Boost patient engagement and medication adherence
•  Heighten patient satisfaction: Patient preference is for shared decision 
making (SDM) and patients appreciate evidence-based guidelines
•  Acknowledges that each case is unique and patient preferences matter
Martin, S.S. et al. J Am Coll Cardiol. 2015; 65(13):1361–8.
The clinician-patient risk discussion (CPRD) is an intersection of evidence, clinical judg-
ment, and patient preference. ACC ¼ American College of Cardiology; AHA ¼ American
Heart Association; ASCVD ¼ atherosclerotic cardiovascular disease; CAC ¼ coronary artery
calcium; CRP ¼ C-reactive protein; CV ¼ cardiovascular; LDL-C ¼ low-density lipoprotein
cholesterol; SDM ¼ shared decision making.
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cognitive impairment, reassurance can be provided
that this is exceedingly rare, if it exists at all (1,38–40).
Patients should also be informed that severe muscle
damage is extremely rare and muscle complaints are
usually no more common in statin-treated patients
than in those given placebo in clinical trials, even in
ones without a drug run-in period (1). Nevertheless,
myalgias and arthralgias are common and impor-
tant issues in real-world settings, and their signiﬁ-
cance—whether causally related or not to statin
therapy—should not be minimized. It may be reassur-
ing that most patients who develop myalgias can
tolerate a statin when rechallenged (41,42), especially
when it is given in a lower dose or less frequently
during the week. A personal or family history of mus-
cle problems should be determined and addressed,
however, before statin therapy is initiated.
If new symptoms develop, the clinician should
be alerted so that they can be evaluated appropri-
ately. Moderate to severe symptoms that are pro-
gressive or concerning should prompt cessation of
statin therapy until a clinical evaluation can occur.
This, in part, is why the guidelines recommend post-
treatment lipid and safety evaluations 3 to 12 weeks
after initiation of statin therapy and then at
intervals thereafter deemed appropriate through the
SDM period.
WHEN TO USE THE APP. The ACC/AHA Risk Esti-
mator app was designed as a resource that could be
used during and between clinical encounters. Some
practices have encouraged patients to download the
app, review information, and enter data to prepare for
a CPRD in advance of the ofﬁce visit. Beyond the in-
ofﬁce uses discussed earlier, patient-centered infor-
mation contained in the app can serve as an ongoing
resource after the visit. This section includes in-
formation on understanding cardiovascular risk,
diet and physical activity recommendations, weight
management recommendations, blood cholesterol
management recommendations, statin beneﬁt groups,
and common cardiovascular terms.
For some patients, the SDM process may span
multiple encounters. After the initial visit, further
testing to reﬁne risk assessment may be pursued or
the patient may desire more time to review infor-
mation before making a decision. As opposed to
decisions in the acute care setting, decisions
regarding chronic therapy (e.g., a statin) are, by
deﬁnition, less pressured, and patients should be
given adequate time to learn about their risk status
and treatment options. Goals of this process include
alignment with the patients’ values and preferences,
along with engagement of the patients in their care.
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Appendix 2.
POTENTIAL BARRIERS TO IMPLEMENTATION:
ADDRESSING COMMON CONCERNS
“MY PATIENT ISN’T 40 TO 75 YEARS OLD”. Patients
falling outside the age boundaries of the ASCVD risk
estimator present an added opportunity to exercise
clinical judgment and weigh patient preference be-
cause there is less evidence to guide clinical decision
making. For patients <40 years of age, we recommend
prioritizing discussion about lifetime risk and other
selected risk factors (particularly family history and
LDL-C $160 mg/dl). For patients $75 years of age, we
recommendpayingparticular attention to thepotential
for adverse effects (e.g., from drug-drug interactions).
“I DON’T AGREE WITH THE CONTENT”. Clinicians
who disagree with the guidelines’ core content and
associated decision aids may ﬁnd that their beliefs
prohibit implementation. For example, some clini-
cians have raised concerns that women may not
tolerate statins as well as men do and the associated
beneﬁt may be less. Such is not the case in secondary
prevention trials, where strong evidence exists that
women derive the same magnitude of beneﬁt as men
in terms of the reduction in nonfatal ASCVD events
(1). Whereas the guidelines acknowledge that less
data are available in primary prevention, results from
multiple trials (43,44) support the selective use of
statins in women who are at a sufﬁcient level of
estimated risk. The new guidelines’ use of separate
risk equations by sex and race should decrease the
number of white women who would have been given
statins based only on a mildly elevated LDL-C,
instead focusing treatment on those most likely to
beneﬁt. Treatment decisions ultimately reside with
the patient and it is the responsibility of the clinician
to share information that is scientiﬁcally accurate and
bias-free with their patients (45).
“I ALREADY DO THIS”. Many clinicians already carry
out CPRDs. Nonetheless, a systematic review sug-
gested that most could improve (46). A study of well-
educated, afﬂuent patients from the West Coast of the
United States who participated in focus groups
conveyed a reluctance to disagree or assert their
preference for fear of being perceived as difﬁcult and
compromising their quality of care (47). Moreover, a
study formally asking clinicians what their patients
believe found that physicians tend to misdiagnose
patients’ health beliefs and preferences (48). On this
basis, it should come as no surprise that long-term
adherence to evidence-based medical therapies,
including statins, is only about 50% (49).Concentrating efforts on high-quality CPRD offers
an opportunity to strengthen clinician-patient re-
lationships, patient engagement, and medication
adherence (9). In our own practices, we ﬁnd that
patients appreciate the opportunity to discuss the
meaning of their estimated risk and lipid results, their
other nonlipid risk factors and what to do about them,
components of a healthy lifestyle and how they may
be incorporated, and the potential role of statin
therapy. Our patients appreciate that evidence-
based guidelines exist to inform these discussions,
but judgment is required, and they appreciate that
guidelines with thresholds of estimated risk do not
mandate medication prescription.
“I DON’T HAVE THE TIME”. We have heard colleagues
say that the CPRD is difﬁcult, too involved and time-
consuming, and may not be practically implemented
in an era of appointments lasting <15 min. However,
in a nation where almost 1 in 3 people will die of a
myocardial infarction or stroke and almost 6 of 10 will
have an event before they die, it seems prudent to
endorse a CPRD. For straightforward cases, a CPRD
may take <5 min. For more complicated cases, it may
take a full visit or multiple visits to ensure that all
elements have been discussed, the patient has
had enough time to consider the options, and the
patient’s questions are fully answered. Working with
patients on the issues of greatest consequence
to their health—is this not precisely what we are
supposed to do?
Some physicians, such as those in busier practices,
may work with other members of the care team on
the CPRD. For example, a nurse practitioner or
physician assistant may initiate the discussion, pre-
sent evidence, and elicit patient preferences, to be
later joined by the physician in the SDM process.
Additionally, portions of the CPRD may then be
reinforced and extended by other care team mem-
bers, such as a dietitian who builds on the initial diet
discussion. We not only need dedicated and collabo-
rative clinicians, but also reimbursement models that
value these team-based efforts.
Pay for process could be a reasonable option that
does not discriminate against clinicians who treat
those with the toughest problems (e.g., statin intol-
erance) and those with the fewest resources. For
example, a reasonable process-based goal in pri-
mary prevention could be documentation that each
component of the CPRD checklist was addressed
(Table 1). This could be easily accomplished collabo-
ratively in one’s electronic health record with a dot or
smart phrase, or via the ACC/AHA Risk Estimator app
if integrated into the electronic health record. Such an
approach is compatible with recommendations from
J A C C V O L . 6 5 , N O . 1 3 , 2 0 1 5 Martin et al.
A P R I L 7 , 2 0 1 5 : 1 3 6 1 – 8 Clinician-Patient Risk Discussion
1367implementation science leaders to use checklists to
enhance guideline implementation (50).
CONCLUSIONS
Conceptually, the CPRD has been summarized as an
intersection between evidence, clinical judgment,
and patient preference (Central Illustration). It is dy-
namic in nature, as clinicians and patients will focus
on a variety of issues over time, including review
of medication types and doses. The CPRD respects
the autonomy of patients as the persons who are
balancing the expected risks and available therapeu-
tic options to reach decisions that best ﬁts with their
preferences. Whereas the patient makes the decision,
the physician provides essential guidance and may
adjust the content and strength of their guidancebased on the patient’s clinical proﬁle, learning style,
and comfort in making the decision. Shining the
spotlight on CPRD serves as a reminder that we are
not treating only numbers, but rather we are
addressing the cardiovascular health concerns of
individual patients.
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